Timing and dosage may be the key in the realisation of hydroxychloroquine + azithromycin treatment benefit in Covid-19 elderly patients
- 1 April 2021
- journal article
- letter
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 57 (4) , 106314
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Hydroxychloroquine in Hospitalized Patients with Covid-19New England Journal of Medicine, 2021
- Dexamethasone in Hospitalized Patients with Covid-19New England Journal of Medicine, 2021
- Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysisClinical Microbiology and Infection, 2021
- Pattern of SARS-CoV-2 infection among dependant elderly residents living in long-term care facilities in Marseille, France, March–June 2020International Journal of Antimicrobial Agents, 2020
- The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the HorseInfectious Diseases and Therapy, 2020
- Beyond Anti-viral Effects of Chloroquine/HydroxychloroquineFrontiers in Immunology, 2020
- Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) InfectionJAMA Network Open, 2020